sar425899 sanofi dual glp-1 glucagon agonist How glucagon-like peptide 1 receptor agonists work The molecular pharmacology of glucagon

Key findings from the studies include: A big drop in the apnea-hypopnea index (AHI) for those on tirzepatide

Diabetes Care 2012

The diagram to the right details how to help minimise side effects from treatment with GLP-1s

Muscle loss during GLP-1 weight loss is typically linked to: Low protein intake Large calorie deficits Reduced resistance training Rapid or unstructured weight loss Weight loss always includes a mix of fat and lean mass loss, but research on GLP-1 medications suggests that while fat loss is predominant, some lean mass loss can occur depending on dietary intake and physical activity levels

Ongoing clinical trials are planned, including evaluating tirzepatide as adjunctive therapy in individuals with a BMI over 27 who are already receiving infliximab or adalimumab treatment (NCT06774079)

The first solution to any weight loss always should be diet and exercise